Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/2667
Title: | The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells | Authors: | Pejin B. Tommonaro G. Glumac M. Jakimov D. Kojić, Vesna |
Issue Date: | 4-Mar-2018 | Journal: | Natural Product Research | Abstract: | © 2017 Informa UK Limited, trading as Taylor & Francis Group. This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time. Compared both with avarol and positive controls used (temozolomide and doxorubicin), avarone was found to be the most active compound with IC50 value below 1 μM (IC50 0.68 ± 0.04 μM, 96 h). Considerable less DNA damage in the cells treated with avarol and avarone vs. doxorubicin (105 & 123% vs. 299%, respectively; untreated U-251 MG cells were used as a control, 100%), coupled with no sign of cytotoxicity against the normal human foetal lung fibroblast MRC-5 cells (IC50 > 100 μM), has actually pointed out the importance of this marine sesquiterpenoid quinone structure as a promising lead compound in development of novel brain chemotherapeutics. | URI: | https://open.uns.ac.rs/handle/123456789/2667 | ISSN: | 14786419 | DOI: | 10.1080/14786419.2017.1327959 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
8
checked on May 10, 2024
Page view(s)
20
Last Week
7
7
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.